CN105595341A - Lycopene composition with oxidation resistance and asthenopia relieving effects - Google Patents
Lycopene composition with oxidation resistance and asthenopia relieving effects Download PDFInfo
- Publication number
- CN105595341A CN105595341A CN201610060020.7A CN201610060020A CN105595341A CN 105595341 A CN105595341 A CN 105595341A CN 201610060020 A CN201610060020 A CN 201610060020A CN 105595341 A CN105595341 A CN 105595341A
- Authority
- CN
- China
- Prior art keywords
- lycopene
- oxidant
- powder
- alleviating asthenopia
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 title claims abstract description 88
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 title claims abstract description 87
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 title claims abstract description 87
- 239000001751 lycopene Substances 0.000 title claims abstract description 87
- 235000012661 lycopene Nutrition 0.000 title claims abstract description 87
- 229960004999 lycopene Drugs 0.000 title claims abstract description 87
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 24
- 230000000694 effects Effects 0.000 title abstract description 11
- 230000003647 oxidation Effects 0.000 title abstract description 5
- 238000007254 oxidation reaction Methods 0.000 title abstract description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims description 43
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 24
- 240000003394 Malpighia glabra Species 0.000 claims description 24
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 24
- 239000012141 concentrate Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 22
- 230000003078 antioxidant effect Effects 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 12
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000005507 spraying Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims 2
- 235000019693 cherries Nutrition 0.000 claims 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 2
- 239000001116 FEMA 4028 Substances 0.000 abstract description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract description 2
- 229960004853 betadex Drugs 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000008990 Prunus myrtifolia Nutrition 0.000 abstract 2
- 240000000540 Prunus myrtifolia Species 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 description 13
- 210000001508 eye Anatomy 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- 235000012680 lutein Nutrition 0.000 description 6
- 239000001656 lutein Substances 0.000 description 6
- 229960005375 lutein Drugs 0.000 description 6
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 6
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- -1 carotenoid fatty acid ester Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000779599 Malpighia Species 0.000 description 1
- 244000007729 Malpighia coccigera Species 0.000 description 1
- 235000014791 Malpighia coccigera Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a lycopene composition with oxidation resistance and asthenopia relieving effects. The composition is prepared from, by weight, 10-50 parts of lycopene oil, 10-50 parts of lutein ester and 10-50 parts of west Indies cherries. Lycopene, lutein ester and west Indies cherries have a synergistic effect and have better oxidation resistance and asthenopia relieving effects. Meanwhile, the invention further discloses a technology for wrapping beta-cyclodextrin on lycopene oil, the problem that lycopene oil is not stable is effectively solved, and the quality of the product is improved.
Description
Technical field
The invention belongs to field of health care food, be specifically related to a kind of lycopene sheet with anti-oxidant, alleviating asthenopia andPreparation method.
Background technology
Lycopene claims again ψ-carrotene, belongs to isoprene compounds, is the one of carotenoid. Due toEarly from tomato, separate and make, therefore claim lycopene. Lycopene is by physics and chemistry mode quenching singlet oxygen or seizurePeroxylradicals. Singlet oxygen is to have very strong active oxygen radical, and tool cytotoxic effect, with cell membrane, line grainThe positions such as body are the most responsive to it, can have an effect with multiple large biological molecule in cell, by being combined and causing cell with moleculeThe damage of film system; Lycopene can be accepted the energy of different excited electronic states, absorbs luminous energy and passes through singlet-single lineState energy transfer process makes the energy of singlet oxygen transfer to lycopene, generates ground state oxygen molecule and triplet lycopene and dividesSon, triplet lycopene is by reacting and regenerated with a series of optically-actives of solvent and vibration, and in this process by energyDistribute; In the quencher ability of carotenoid and its molecule, the number of contained conjugated double bond has close relationship, tomatoIn red pigment molecule, have 11 conjugated double bonds, a lycopene molecule can be removed thousands of singlet oxygens, its quencher singletThe speed constant of oxygen is high 2 times compared with beta carotene. Nineteen ninety Paolo etc. has reported carotenoid and tocopherol etc. more than 30The effect of planting biological anti-oxidant quenching singlet oxygen, lycopene is that quenching singlet oxygen is the strongest. Meanwhile, lycopeneBe present in a large number various mucous membrane tissues in body, long-term taking can improve various various because of what in body, mucous membrane tissue destruction was causedUncomfortable. As dry and astringent in dry cough, eyes, canker sore, protection gastrointestinal tract mucosa tissue etc.
Lutein ester is a kind of important carotenoid fatty acid ester, and its stability is better than lutein, only at high temperature, strongUnder the factors such as acid, iron ion and oxygen, destroy larger to lutein ester. Lutein ester is decomposed into free state leaf Huang after absorption of human bodyElement, has crystal lutein and supplements the basic function of human body loss lutein. And the importance of lutein is in global nutritionBoundary all obtains certainly, and why the macula area of eye is yellow color, exactly because it has been full of lutein and homologous series thing thereof.Lutein filters blue light and oxidation resistant effect, is the crucial nutrient that helps eye development. Therefore, there is people also leaf HuangElement likens " stealthy sunglasses " to.
Acerola concentrate is the fruit of the recessed edge Malpighia coccigera of Malpighiaceae Malpighia, and acerola concentrate is to support one's family in the plant of planting at presentElement C content third high, in every 100 grams of fruits, Vc content reaches 1677 milligrams, is only second to Ka Kaduli and Ka Mu fruit, is31 times of lemon, 27 times of strawberry, 18 times of Kiwi berry, are to be also considered to 7 times of the high guava of vitamin C,Be one of genuine " king of natural complex C ", also contain the elements such as dimension A, dimension B1, dimension B2, iron, calcium simultaneously,Vitamin C is to maintain the integral important composition of human life, and it can anti-ly be caught a cold, and anti-scurvy is improved human body opposingAbility, has certain effect to beauty treatment and cancer. Aspect health care, beverage, beauty treatment, be widely used.
Embedding techniques (microencapsulation) claim again microcapsules technology, refers to and utilize natural or synthetic macromolecular material (to lead toBe called wall material), by solid, liquid or gas material (being commonly referred to as heartwood), the one forming through packing has semi permeability or closeThe technology of envelope cyst membrane microencapsulation, extensive use in the fields such as pharmacy, food, spices, agricultural chemicals. Beta-schardinger dextrin-(β-Cyclodextrin, β-CD) is the wall material of most study, and it is formed by connecting with α-Isosorbide-5-Nitrae glycosidic bond by 7 glucose molecules,Main body conformation is that a centre has cavity, the cylinder that two ends are not sealed, and its significant architectural feature is to have a three-dimensional tubularChirality hydrophobic cavity, special nonpolar hydrophobic environment makes β-CD can be with active forces such as Van der Waals force, hydrophobic and hydrogen bonds, withThe hydrophobic group effect of the molecule that some polarity, size, shape and character match or some molecule, at its space structureIn all or part ofly wrap into another kind of molecule and form stable supermolecule inclusion compound, claim beta-CD inclusion or β-CD moleculeMicro-capsule. In inclusion compound, outer field β-CD is called host molecule, and the small-molecule substance by inclusion within host molecule is called visitor pointSon (heartwood). Because beta-schardinger dextrin-has hydrophilic surface relative to, a relatively hydrophobic center, enclosed molecule material is inlayedIn centre, in use both can be uniformly dispersed, again enclosed molecule material is played to certain protective effect.
In lycopene molecule, there are 11 conjugated double bonds and 2 unconjugated double bonds, make the stability of lycopene poor,Can there is cis-trans isomerization and oxidative degradation under certain condition, cause lycopene formulations unstable, so tomato on the marketRed pigment formulation is generally soft capsule, but soft capsule technological requirement is high, and cost is high.
Summary of the invention
The object of the invention is to overcome above-mentioned weak point, provide a kind of can be safely, effectively anti-oxidant, alleviating asthenopiaLycopene composition.
Another object of the present invention is to provide the preparation method of this lycopene composition tablet.
A further object of the invention is to provide this tablet can be effectively anti-oxidant, the application of alleviating asthenopia.
The object of the invention is to realize in the following manner:
Have a lycopene composition anti-oxidant, alleviating asthenopia, it is made up of the component of following weight portion: tomatoRed pigment oil 10-50 part, lutein ester 10-50 part, acerola concentrate powder 10-50 part.
Above-mentioned have lycopene composition anti-oxidant, alleviating asthenopia and be preferably made up of the component of following weight portion: tomatoRed pigment oil 45-50 part, lutein ester 10-20 part, acerola concentrate powder 10-20 part.
Said composition can be made preparation with the acceptable auxiliary material of pharmacy, preferred formulation be tablet, capsule, granule, pill,Oral liquid.
Above-mentioned tablet is mainly made up of the component of following weight portion: lycopene oil 10-50 part, and lutein ester 10-50 part,Acerola concentrate powder 10-50 part, beta-schardinger dextrin-10-100 part.
Preferred tablet is mainly made up of the component of following weight portion: lycopene oil 45-50 part, and lutein ester 10-20 part,Acerola concentrate powder 10-20 part, beta-schardinger dextrin-50-90 part.
In this tablet, also comprise emulsifying agent and food stage auxiliary material. Food stage auxiliary material can, as the filler that is pressed into tablet, lubricateAgent, bonding agent etc.
Described emulsifying agent is preferably: Tween-80, and monoglyceride, three polyglycerol esters, soybean lecithin, lauric monoglyceride,At least one or several mixing in stearoyl lactate, emulsifier is the 0-1% of lycopene weight of oil; Food stage auxiliary materialFor: cornstarch, D-sorbite, maltodextrin, microcrystalline cellulose, lactose, dolomol, at least one in antierythritePlant or several mixing, consumption is the 1%-10% of the weight of lutein ester, acerola concentrate powder and lycopene powder gross weight.
The preparation method of the lycopene sheet with anti-oxidant, alleviating asthenopia of the present invention comprises the following steps:
A. get in beta-schardinger dextrin-is dissolved in 50-80 DEG C distilled water as wall material, constant temperature 10-50min, adds emulsifying agent and workFor the lycopene oil of core, homogeneous, spraying is dried to obtain lycopene powder;
B. get lutein ester, acerola concentrate powder and lycopene powder and mix, then with food stage auxiliary materials and mixing, compressing tablet and get final product.
Processing condition in described step a: temperature 20-60 DEG C, pressure 10-40MPa. Spraying drying condition: injector temperature100-200 DEG C, outlet temperature 50-100 DEG C, flow velocity 500-1500ml/h.
Raw material used in the present invention: lycopene oil (Shaanxi Sen Fu natural product Co., Ltd, lycopene >=10%),Lutein ester (Xi Anyue reaches biotech inc, lutein ester >=90%), acerola concentrate powder (Hainan Si TandeBio tech ltd, VC content >=10%).
Beneficial effect of the present invention compared with the prior art:
1, the present invention, by lutein ester, acerola concentrate powder and three kinds of materials of lycopene in conjunction with application, plays Synergistic and doesWith, proving through concrete function evaluation experimental, the present invention plays the better effect of anti-oxidant, alleviating asthenopia.
2, lycopene oil is general only for soft capsule dosage form, and due to the special nature of raw material, soft capsule dosage form has been difficult toThe combination of many kinds of substance of the present invention, the present invention is in conjunction with specific auxiliary material, adopts special beta-schardinger dextrin-embedding lycopene oilTechnology, when effectively solving lycopene oil instability problem, also enables with lutein ester and acerola concentrate powder effectiveIn conjunction with, the tablet being not only prepared into meets preparation requirement, and bioavilability also can significantly improve.
3, tablet of the present invention overcomes Lycopene Tablets by UV Spectrophotometry wild effect, and with low cost, taking convenience.
Have anti-oxidant, alleviating asthenopia by concrete test of pesticide effectiveness example is further illustrated to lycopene sheet of the present invention belowEffect.
One, asthenopia releasing function evaluation experimental
1. materials and methods
Sample and placebo: lycopene sheet of the present invention No. 1, No. 2, both are in packaging, outward appearance, color and luster and mouthfeelBasically identical, lycopene sheet is for No. 1 lycopene sheet of the present invention (preparing according to embodiment 1 method), anotherIndividual is placebo. People oral every day 1 time, each 1.
2. experimenter selects
Experimenter's mass selection is selected: select long-term with eye, the fatigable adult of eyesight. All richnesses meet above-mentioned condition and voluntary participation alsoEnsure that cooperation person all can include test in.
3. test method
Adopt two kinds of control design between self and group, according to requirement random, double blinding, will meet inclusive criteria and ensure and coordinateTest volunteer, according to symptom, eye test situation, consider simultaneously the factor such as age, sex be divided into tested group andControl group. Tested group and control group are taken sample or placebo by RD, continuous 45 days. Duration of test does not change formerThe eating habit, the normal diet that come.
4, efficiency index
Symptom Observation: inquire in detail visual fatigue situation, observe the symptoms such as ophthalmodynia, swollen, the photophobia of eye, eye be dry and astringent, by mild symptomsMultiple integral (3 points of severes, 2 points of middle diseases, 1 point of light disease), statistics integrated value before and after test-meal, and improve and (appoint with regard to its symptomOne symptom is improved 1 point above for improving) situation, improvement rate observes the symptoms.
Photophobia, blurred vision, the dry and astringent arbitrary symptom of eye are improved 1 point and 1 point and are above improvement, 5 kinds of arbitrary changing of symptomKind other symptoms judge symptom improvement without worsening.
5. result
5.1, ordinary circumstance: initial trial crowd's test group 54 examples, control group 54 examples, test-meal group: male/female is 19/53,Age is 51.61 ± 11.39 years old; Control group: male/female is 20/34, the age is 51.15 ± 11.57 years old. Tested during test-mealPerson's spirit, sleep, diet, stool and urine are all normal.
5.2, functional observation
In table 1 and table 2, test-meal group ophthalmodynia after test-meal, eye is swollen, photophobia, blurred vision, eye are dry and astringent etc., and clinical symptoms have brightAobvious improvement, obvious reduction before its symptom integral and test-meal, difference has conspicuousness (P < 0.05), with control group comparison,Difference also has conspicuousness (P < 0.05).
Symptom integral statistics before and after table 1 tablet test-meal of the present invention
Before and after table 2 tablet test-meal of the present invention, symptom is improved situation
Experimental result shows: lycopene sheet of the present invention is dry and astringent etc. clinical to ophthalmodynia, swollen, the photophobia of eye, blurred vision, eyeSymptom is improved, and after test, the front and control group comparing difference of test-meal group symptom integral and test-meal has conspicuousness (P < 0.05);There is conspicuousness (P < 0.05) with control group comparing difference, prove that tablet of the present invention has function of relieving visual fatigue.
Two, anti-oxidation function evaluation experimental
1, materials and methods
1.1 sample
Lycopene sheet of the present invention (preparing according to embodiment 1 method), without lycopene negative control sample, tomatoRed pigment powder (preparing according to embodiment 1 method).
1.2 animal
Select the 12 monthly age male mices by the breeding of Qinglongshan animal reproduction field, Jiangning county.
The selection of 1.3 dosage
Tablet dosage of the present invention is adult 4 of (body weight 60kg) every days, and every 3g, is equivalent to 0.2g/ day/kg. AdministrationGroup rat 2 per os every day give, and rat oral gavage volume is that 0.01g/100g mouse is heavy, and sample adopts water-soluble rear gavage. SimultaneouslyIf 3 groups of control groups, blank group water replaces tablet of the present invention, and every day, gavage was identical with embodiment sample sets consumption. Tomato redElement powder group gavage every day is identical with embodiment sample sets consumption, and without lycopene group, (preparation method is with embodiment 1, Jin JinshiThe few lycopene oil of component) every day gavage identical with embodiment sample sets consumption.
2, experimental technique
Give not the test solution that is subject on the same group according to the dosage design gavage in 1.3, every day gavage once, gavage volume is0.1ml/10gbw, continuous 30 days. The 31st day, on Mouse Tail-tip, the content of MDA was measured in blood sampling, and plucked eyeball blood sampling,Centrifugal, get serum, measure serum superoxide dismutases (SOD) vigor and glutathione peroxidase (GSH-PX) and livePower, t inspection between product test method employing group.
3, result
Table 3 separate groups of mice SOD vigor and GSH-PX vigor
| Group | Number of cases | SOD(U/ml) | GSH-PX(U/L) |
| Blank group | 12 | 154.31±27.11 | 537.1±71.2 |
| 1 group of embodiment | 12 | 271.23±37.72 | 731.3±67.7 |
| Lycopene powder group | 12 | 178.92±29.13 | 610.3±59.3 |
| Without lycopene group | 12 | 163.21±31.21 | 598.4±61.2 |
Visible in table 3, embodiment group SOD in Mice vigor and GSH-PX vigor, higher than other groups, illustrate of the present inventionAgent has oxidation resistant effect, simultaneously the embodiment of the present invention 1 tablet antioxidant effect and independent lycopene powder group and the nothing of usingLycopene group more all has significant difference.
Use embodiment 1 tablet to carry out safety testing
Rat 30d feeding trial: rat gives standard feed, raises in (20 ± 3) DEG C, humidity (40 ± 5) %, artificial lightUnder 10h environment, timing ventilation. Adapt to, after 5d, be divided at random 4 groups, 20 every group, male and female half and half. If low, in,High 3 dosage groups, dosage is respectively 1.0,2.5,5.0g/kg, separately establishes negative control group, adopts gastric infusion every day, givesBefore medicine, mix liquid, gavage amount is 1.0ml/kg body weight. Observe and record rat clinical manifestation every day, every 5d claims body one timeHeavy and food is taken the photograph people's amount, calculates efficiency of feed utilization. 30d after administration, gets respectively 10 animals, carries out following for every groupCheck: (1) hematological examination: pluck eyeball blood sampling, meet 1mL in heparin tube, survey red blood cell (RBC), hemoglobin (HB),Packed cell volume (HCT), mean corpuscular volume (MCV) (MCV), mean corpuscular hemoglobin (MCH), leucocyte(WBC), lymphocyte (LYM), monocyte (MO), neutrophil leucocyte (GR) and blood platelet (PLT) content.
Give lycopene tablet rat blood and learn check result
Rat 30d feeding trial result shows, senior middle school's low dose group hematological indices and control group, without significant difference, prove thisInvention lycopene sheet edible safety.
Detailed description of the invention
Form by the following examples, is described in further detail foregoing of the present invention again, but this should not understoodFor the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong toScope of the present invention.
Embodiment 1:
Main formula:
Lycopene oil 500g, lutein ester 100g, acerola concentrate powder 100g, beta-schardinger dextrin-500g.
Preparation method:
A. get beta-schardinger dextrin-and be dissolved in 50 DEG C of distilled water, constant temperature 30min, adds 1% emulsifying agent list of lycopene weight of oilSweet ester and lycopene oil (core and wall material ratio are 1:1), homogeneous, processing condition temperature 50 C, pressure 30MPa, sprayMist is dried to obtain lycopene powder, spraying drying condition: 150 DEG C of injector temperatures, 75 DEG C of outlet temperatures, flow velocity 1500ml/h.
B. get lutein ester, acerola concentrate powder and lycopene powder and mix, then (Fructus Hordei Germinatus is stuck with paste with maltodextrin and microcrystalline celluloseEssence and microcrystalline cellulose weight ratio 1:1, consumption be lutein ester, acerola concentrate powder and lycopene powder gross weight 1%),Mix, compressing tablet and get final product, the heavy 0.4g of sheet, amounts to 3000.
| Embodiment 1 tablet index | |
| Weight differential | -0.3-0.9％ |
| Disintegration time limited | 17min |
| Microbial limit | Qualified |
Embodiment 2:
Main formula:
Lycopene oil 450g, lutein ester 100g, acerola concentrate powder 100g, beta-schardinger dextrin-900g.
Preparation method:
A. get beta-schardinger dextrin-and be dissolved in 80 DEG C of distilled water, constant temperature 30min, adds 0.5% emulsifying agent of lycopene weight of oilSoybean lecithin and lycopene oil (core and wall material ratio are 1:2), homogeneous, 30 DEG C of processing condition temperature, pressure 40MPa,Spraying is dried to obtain lycopene powder, spraying drying condition: 170 DEG C of injector temperatures, 85 DEG C of outlet temperatures, flow velocity 1000ml/h. ;
B. get lutein ester, acerola concentrate powder and lycopene powder and mix, then (consumption is with food stage microcrystalline cellulose excipientsLutein ester, acerola concentrate powder and lycopene powder gross weight 3%) mix compressing tablet and get final product, the heavy 0.4g of sheet.
| Embodiment 2 tablet indexs | |
| Weight differential | -0.3-0.9％ |
| Disintegration time limited | 17min |
| Microbial limit | Qualified |
Embodiment 3:
Main formula:
Lycopene oil 180g, lutein ester 180g, acerola concentrate powder 180g, beta-schardinger dextrin-900g.
Preparation method:
A. get beta-schardinger dextrin-and be dissolved in 80 DEG C of distilled water, constant temperature 30min, adds 0.5% emulsifying agent of lycopene weight of oilSoybean lecithin and lycopene oil (core and wall material ratio are 1:5), homogeneous, 30 DEG C of processing condition temperature, pressure 40MPa,Spraying is dried to obtain lycopene powder, spraying drying condition: 170 DEG C of injector temperatures, 85 DEG C of outlet temperatures, flow velocity 1000ml/h. ;
B. get lutein ester, acerola concentrate powder and lycopene powder and mix, then (consumption is with food stage microcrystalline cellulose excipientsLutein ester, acerola concentrate powder and lycopene powder gross weight 3%) mix compressing tablet and get final product, the heavy 0.4g of sheet.
| Embodiment 3 tablet indexs | |
| Weight differential | -0.3-0.9％ |
| Disintegration time limited | 17min |
| Microbial limit | Qualified |
Claims (10)
1. there is a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in that it is by following weight portionComponent is made: lycopene oil 10-50 part, lutein ester 10-50 part, acerola concentrate powder 10-50 part.
2. according to claim 1 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatIt is made up of the component of following weight portion: lycopene oil 45-50 part, lutein ester 10-20 part, acerola concentrate powder 10-20Part.
3. according to claim 1 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatThe acceptable auxiliary material of said composition and pharmacy is made preparation, and preferred formulation is tablet, capsule, granule, pill, oralLiquid.
4. according to claim 3 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatDescribed tablet is mainly made up of the component of following weight portion: lycopene oil 10-50 part, lutein ester 10-50 part, pinLeaf cherry powder 10-50 part, beta-schardinger dextrin-10-100 part.
5. according to claim 4 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatDescribed tablet is mainly made up of the component of following weight portion: lycopene oil 45-50 part, lutein ester 10-20 part, pinLeaf cherry powder 10-20 part, beta-schardinger dextrin-50-90 part.
6. according to claim 4 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatAlso comprise emulsifying agent and food stage auxiliary material.
7. according to claim 6 have a lycopene composition anti-oxidant, alleviating asthenopia, it is characterized in thatDescribed emulsifying agent is: Tween-80, monoglyceride, three polyglycerol esters, soybean lecithin, lauric monoglyceride, stearoyl breastAt least one or several mixing in acid sodium, emulsifier is the 0-1% of lycopene weight of oil; Food stage auxiliary material is: cornStarch, D-sorbite, maltodextrin, microcrystalline cellulose, lactose, dolomol, in antierythrite at least one or severalMix, consumption is the 1%-10% of lutein ester, acerola concentrate powder and lycopene powder gross weight.
8. the system of the lycopene sheet with anti-oxidant, alleviating asthenopia described in claim 4-7 any one claimPreparation Method, is characterized in that the method comprises the following steps:
A. get in the distilled water that beta-schardinger dextrin-is dissolved in 50-80 DEG C, constant temperature 10-50min, adds emulsifying agent and lycopene oil,Homogeneous, spraying is dried to obtain lycopene powder;
B. get lutein ester, acerola concentrate powder and lycopene powder and mix, then with food stage auxiliary materials and mixing, compressing tablet and get final product.
9. the preparation method of the lycopene sheet with anti-oxidant, alleviating asthenopia according to claim 8, its spyLevy and be processing condition in described step a: temperature 20-60 DEG C, pressure 10-40MPa.
10. the preparation method of the lycopene sheet with anti-oxidant, alleviating asthenopia according to claim 8, its spyLevy and be to spray in described step a drying condition: injector temperature 100-200 DEG C, outlet temperature 50-100 DEG C, flow velocity500-1500ml/h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060020.7A CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060020.7A CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105595341A true CN105595341A (en) | 2016-05-25 |
| CN105595341B CN105595341B (en) | 2018-12-04 |
Family
ID=55976144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610060020.7A Active CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105595341B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106579111A (en) * | 2016-11-29 | 2017-04-26 | 广州汇圣森丰农业科技发展有限公司 | Black tomato chewable tablet with anti-oxidation effect |
| CN106723012A (en) * | 2016-11-19 | 2017-05-31 | 乌鲁木齐市疆域绿色营养源研究院（有限公司） | A kind of lycopene powder and compound fruit and vegetable piece |
| CN109419775A (en) * | 2017-08-25 | 2019-03-05 | 南京生矶坊生物工程有限公司 | A kind of water-soluble lycopene and its preparation method and application |
| US11723879B2 (en) * | 2017-12-08 | 2023-08-15 | Chenguang Biotech Group Co., Ltd. | Lycopene micro-capsule powder and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813763A (en) * | 2005-02-04 | 2006-08-09 | 南京师范大学 | Lycopene/beta-cyclodextrin supermolecular composition and its preparation |
| US20100004330A1 (en) * | 2008-07-02 | 2010-01-07 | Li Lin Huang | Anti-oxidative content material used in drink and food manufacturing method |
| CN103735733A (en) * | 2013-12-30 | 2014-04-23 | 杭州海杭生物医药科技有限公司 | Compound preparation containing lutein ester and preparation method thereof |
-
2016
- 2016-01-28 CN CN201610060020.7A patent/CN105595341B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813763A (en) * | 2005-02-04 | 2006-08-09 | 南京师范大学 | Lycopene/beta-cyclodextrin supermolecular composition and its preparation |
| US20100004330A1 (en) * | 2008-07-02 | 2010-01-07 | Li Lin Huang | Anti-oxidative content material used in drink and food manufacturing method |
| CN103735733A (en) * | 2013-12-30 | 2014-04-23 | 杭州海杭生物医药科技有限公司 | Compound preparation containing lutein ester and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 中国保健协会等: "《营养素的奥秘》", 29 February 2012, 世界图书出版西安有限公司 * |
| 金鑫等: "缓解视疲劳功能食品及其功效成分研究进展", 《食品科学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106723012A (en) * | 2016-11-19 | 2017-05-31 | 乌鲁木齐市疆域绿色营养源研究院（有限公司） | A kind of lycopene powder and compound fruit and vegetable piece |
| CN106579111A (en) * | 2016-11-29 | 2017-04-26 | 广州汇圣森丰农业科技发展有限公司 | Black tomato chewable tablet with anti-oxidation effect |
| CN109419775A (en) * | 2017-08-25 | 2019-03-05 | 南京生矶坊生物工程有限公司 | A kind of water-soluble lycopene and its preparation method and application |
| CN109419775B (en) * | 2017-08-25 | 2021-02-09 | 南京生矶坊生物工程有限公司 | Water-soluble lycopene and preparation method and application thereof |
| US11723879B2 (en) * | 2017-12-08 | 2023-08-15 | Chenguang Biotech Group Co., Ltd. | Lycopene micro-capsule powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105595341B (en) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017214669B2 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
| CN104739921B (en) | A kind of prescription lozenge and preparation method thereof for alleviating visual fatigue | |
| CN104839688A (en) | Eye care preparation and preparation method thereof | |
| CN106236739B (en) | Contain lutein/lutein ester composition and its application | |
| CN108402465A (en) | A kind of micro-capsule compound powder and its preparation process containing peculiar smell oils | |
| CN104783181A (en) | Astaxanthin-containing composition and preparation method thereof | |
| CN103417733B (en) | A kind of pharmaceutical composition of alleviating asthenopia | |
| CN105595341A (en) | Lycopene composition with oxidation resistance and asthenopia relieving effects | |
| CN103735616A (en) | Microencapsulated preparation for protecting eyesight and preparation method thereof | |
| CN107837288A (en) | A kind of compound anthocyanidin lutein ester soft capsule for alleviating visual fatigue | |
| US10299492B2 (en) | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same | |
| CN104474018A (en) | Health-care soft capsule for relieving asthenopia | |
| CN107050438A (en) | Beautiful-skin-promoagent agent and use thereof | |
| CN108294305A (en) | Alleviation visual fatigue composition containing procyanidine | |
| CN109619566A (en) | A kind of nutraceutical for alleviating asthenopia | |
| CN105030877A (en) | Healthcare food for relieving asthenopia and preparation method thereof | |
| JP6336373B2 (en) | Processed food containing marigold extract | |
| CN107440036A (en) | A kind of Halth-care composition, its preparation and preparation method for improving memory, improving eyesight | |
| CN108968069A (en) | Alleviate asthenopia, improves eyesight, is anti-oxidant, the composite soft capsule and preparation method of protection retina | |
| CN108902973A (en) | A kind of cowberry lutein particle and preparation method thereof | |
| CN108685974A (en) | A kind of cowberry lutein piece and preparation method thereof | |
| CN102038644A (en) | Lutein water-soluble powder and preparation process thereof | |
| Zhao et al. | Advances in research on natural distribution, biosynthesis, detection, bioactivity, and application of lutein | |
| CN104940273A (en) | Vision improvement healthcare product and preparation method thereof | |
| CN103932179B (en) | A kind of health food and two-step fermentation preparation method thereof releasing the pressure and protect liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yingyan Inventor after: Xu Guohua Inventor after: Shi Hao Inventor after: Tian Zhibin Inventor after: Wang Wenfeng Inventor before: Shi Hao Inventor before: Xu Guohua Inventor before: Tian Zhibin Inventor before: Wang Wenfeng Inventor before: Wang Yingyan |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |